^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    G1-S-specific cyclin-D1 inhibitor

    Related drugs:
    5d
    HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting | N=60 --> 41 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Dec 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • Synribo (omacetaxine mepesuccinate)
    18d
    All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review. (PubMed, Front Oncol)
    We report a case of a 42-year-old patient with EVI1-positive AML harboring the MLL-AF6 fusion gene, who failed to achieve remission after undergoing standard "IA" induction therapy and was then treated with VAH (venetoclax, azacitidine, and homoharringtonine) consolidation chemotherapy. This case suggests that the combination of ATRA with the VAH regimen may demonstrate promising efficacy and an acceptable safety profile in patients with EVI1-positive AML who are refractory to conventional chemotherapy. However, further clinical studies are required to confirm its wider applicability.
    Journal
    |
    AFDN (Afadin, Adherens Junction Formation Factor)
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    26d
    Single-Center Prospective Study of Homoharringtonine Combined with Azacitidine and Venetoclax in the Treatment of Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (ChiCTR2600120015)
    P=N/A, N=60, The First Hospital of China Medical University; The First Hospital of China Medical University
    New trial
    |
    Venclexta (venetoclax) • sorafenib • Xospata (gilteritinib) • azacitidine • Synribo (omacetaxine mepesuccinate)
    1m
    XPO1 inhibitor KPT-330 disrupts the core transcriptional regulatory circuitry of dedifferentiated liposarcoma by modulating the translation process. (PubMed, Oncogene)
    Furthermore, we identify a synergistic antitumor effect between KPT-330 and translation inhibitors, including everolimus and homoharringtonine. Notably, the disruptive impact of KPT-330 on CRC homeostasis extends to other cancer cell lineages, underscoring its broad mechanistic relevance. Collectively, our findings elucidate a novel mechanism through which KPT-330 destabilizes CRC via translational dysregulation and highlight its potential therapeutic utility in combination regimens for DDLPS.
    Journal
    |
    XPO1 (Exportin 1)
    |
    everolimus • Xpovio (selinexor) • Synribo (omacetaxine mepesuccinate)
    1m
    Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study (clinicaltrials.gov)
    P1, N=94, Not yet recruiting, Zhongda Hospital
    New P1 trial
    |
    docetaxel • Nubeqa (darolutamide) • goserelin acetate • Synribo (omacetaxine mepesuccinate)
    1m
    HVA-MPAL: HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). (clinicaltrials.gov)
    P2, N=40, Enrolling by invitation, Guangdong Second Provincial General Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    1m
    Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial. (PubMed, Nat Commun)
    PLD1-inhibitor remodeled phospholipid metabolism, induced ferroptosis and restored QUIZOM response in LSC. Our findings provided the therapeutic and resistant mechanisms of QUIZOM and paved the way for targeted interventions in this AML subtype.
    P2 data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor)
    |
    NPM1 mutation
    |
    Vanflyta (quizartinib) • Synribo (omacetaxine mepesuccinate)
    2ms
    Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) (clinicaltrials.gov)
    P2, N=61, Not yet recruiting, First People's Hospital of Hangzhou
    New P2 trial
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    2ms
    Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1)
    |
    FLT3-ITD mutation • NPM1 mutation
    |
    Venclexta (venetoclax) • azacitidine • decitabine • Synribo (omacetaxine mepesuccinate)
    2ms
    VEN-OM: Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=6, Completed, University of Illinois at Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)